Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01658150
Recruitment Status : Completed
First Posted : August 6, 2012
Results First Posted : December 5, 2018
Last Update Posted : December 5, 2018
Sponsor:
Collaborator:
Brain & Behavior Research Foundation
Information provided by (Responsible Party):
Katherine Burdick, Icahn School of Medicine at Mount Sinai

Brief Summary:
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorder Drug: isradipine Not Applicable

Detailed Description:
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder. Incomplete treatment response can be common in these disorders. While there are medications that are effective at treating positive symptoms, some other symptoms of the disorders are often left only partially treated (cognitive impairment and negative symptoms). This study will begin to address if the medication isradipine might help to treat some of the cognitive problems associated with schizophrenia and schizoaffective disorder. Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel. It is currently approved by the FDA for hypertension.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade
Study Start Date : September 2012
Actual Primary Completion Date : January 2, 2018
Actual Study Completion Date : January 2, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
Drug Information available for: Isradipine

Arm Intervention/treatment
Experimental: isradipine
open label
Drug: isradipine
Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
Other Name: Dynacirc CR




Primary Outcome Measures :
  1. MATRICS Consensus Cognitive Battery (MCCB) Change in Neurocognitive/Functional Measures [ Time Frame: baseline and week 4 ]
    MATRICS Consensus Cognitive Battery (MCCB) as measure of Neurocognitive/Functional Measures is a standardized battery designed to measure cognitive functioning in people with schizophrenia. The MCCB is represented as a composite T score. A t score is a type of standard score computed by multiplying a z-score (how many standard deviations an element is from the mean) by 10 and adding 50.

  2. UPSA Communication Score [ Time Frame: baseline and week 4 ]
    UCSD Performance Skills Assessment (UPSA) - The UPSA is performance-based measure of real-world daily functioning abilities. Participants receive scores for the communication subscale (range = 0-20), with higher score indicating better neurocognitive functioning

  3. Quality of Life (QoL) Scale [ Time Frame: baseline and Week 4 ]
    The QoL is a measure of the perceived satisfaction in an individual's daily life. This 16-item self-report measure is rated on a 7-point scale, ranging from 1 (terrible) to 7 (delighted), with a total score range from 16-112, where higher scores indicate higher satisfaction with daily life.


Secondary Outcome Measures :
  1. Mean Change in PRISE Adverse Event Checklist Score [ Time Frame: up to 4 weeks ]
    The PRISE is a physician-administered checklist of adverse events. PRISE contains 33 items, each defined by an adverse event. Each item is rated on a 3-point scale, ranging from 0 (not present) to 2 (distressing), with a total score range from 0-66, where higher scores indicate more adverse events. Mean change for adverse events at week 4 as compared to baseline

  2. Number of Participants With Normal ECG [ Time Frame: baseline and week 4 ]
    Number of participants with normal ECG readings to confirm inclusion into study and compared at week 4 to baseline

  3. Number of Participants With Normal Chemistry Panel [ Time Frame: baseline and week 4 ]
    Number of participants with normal chemistry panel to confirm inclusion into study at baseline and week

  4. Number of Participants With Normal Complete Blood Count (CBC) [ Time Frame: baseline and week 4 ]
    Number of participants with normal CBC to confirm inclusion into study at baseline and week 4

  5. Abnormal Involuntary Movement Scale (AIMS) [ Time Frame: baseline and Week 4 ]
    Mean change for abnormal involuntary movements throughout the study. The AIMS is a physician-administered scale of abnormal involuntary movements. AIMS consists of 10 items, each defined by a series of movements. Each item is rated on a 5-point scale, ranging from 0 (not observed) to 4 (severe), with a total score range from 0-40, where higher scores indicate abnormal involuntary movements.

  6. Modified Simpson Angus Scale (MSAS) [ Time Frame: baseline and week 4 ]
    Mean change for drug-induced disordered movement throughout the study. The MSAS is a physician-administered scale of abnormal drug-induced movements. MSAS consists of 6 items, each defined by a series of movements. Each item is rated on a 5-point scale, ranging form 0 (not observed) to 4 (most severe), with a total range of 0-24, where higher scores indicate drug-induced disordered movement.

  7. Beck Scale for Suicidal Ideation (SSI) [ Time Frame: up to 4 weeks ]
    a 21-question multiple choice, self-report inventory that is used for measuring the severity of suicidal ideation. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe suicidal ideation symptoms.

  8. Number of Participants With Suicidal Acknowledgments [ Time Frame: up to 4 weeks ]
    Number of participants with Suicidal acknowledgements based on the Columbia Suicide Severity Rating Scales (C-SSRS) - Full range from 0 (low intensity suicidal ideation to 9 (high intensity suicidal ideation).

  9. Number of Participants With a Confirmed SCID-IV [ Time Frame: baseline ]
    Number of participants with confirm diagnosis for inclusion into study using the Structured Clinical Interview for the DSM-IV (SCID-IV)

  10. Brief Psychiatric Rating Scale (BPRS) [ Time Frame: up to 4 weeks ]
    Mean change for positive symptoms throughout the study. BPRS consists of 18 items, each defined by a series of symptoms. Each item is rated on a 7-point scale, ranging from 1 (not observed) to 7 (very severe), with a total score range from 18-126, where higher scores indicate psychiatric symptoms.

  11. Scale for the Assessment of Negative Symptoms (SANS) [ Time Frame: up to 4 weeks ]
    Mean change of negative symptoms throughout the study. SANS consists of 22 items, each defined by a series of symptoms. Each item is rated on a 6-point scale, ranging from 0 (no presence) to 5 (severe presence), with a total range of 0-110, where higher scores indicate negative symptoms.

  12. Hamilton Rating Scale for Depression (HRSD) [ Time Frame: up to 4 weeks ]
    Mean change of symptoms of depression throughout the study. HRSD consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe), with a total score range of 0-56, where higher score indicates more depressive symptoms

  13. Clinical Global Impression Scale (CGI) [ Time Frame: up to 4 weeks ]
    Mean change of clinical impression of severity of psychiatric illness throughout the study. CGI consists of one item, defined by severity of illness. It is rated on a 7-point scale, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients), with a total range score of 1-7, where higher score indicates severity of illness.

  14. Clinician Administered Rating Scale for Mania (CARS-M) [ Time Frame: up to 4 weeks ]
    Mean change of symptoms of mania throughout the study. CARS-M contains 14 items rated from 0 (absent) to 5 (present) and one item scored 0 to 4, with total range from 0 to 74, where higher score indicates manic symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-60
  • DSM-IV schizophrenia or schizoaffective disorder diagnosis
  • Residual phase of illness criteria met at screen and baseline as defined by item scores of equal to or less than 4 on each of the Brief Psychiatric Rating Scale (BPRS) hallucinatory behavior, unusual thought content, conceptual disorganization items
  • Hamilton Rating Scale for Depression (HRSD) equal to or less than 12
  • Baseline Clinician Administered Scale for Mania (CARS-M) score of less than 5
  • Simpson Angus Scale (SAS) total score equal to or less than 6
  • Treatment with at least one but no more than two stably-dosed second-generation antipsychotic medication (other than clozapine) for equal to or greater than 2 months and no changes planned over the 4-week study period

Exclusion Criteria:

  • History of CNS trauma, neurological disorder, ADHD, mental retardation, learning disability, or other non-schizophrenic cause of cognitive impairment
  • DSM-IV diagnosis of substance abuse/dependence within 3 months
  • Pregnant women or women of childbearing age who are not using a medically accepted means of contraception
  • Women who are breastfeeding
  • Active, unstable medical problem that may interfere with cognition
  • Current treatment for hypertension
  • Uncontrolled hypertension
  • Any drug known to interact with isradipine
  • History of GI strictures
  • History of heart disease
  • Abnormal lab or ECG at screen
  • Significant suicidal ideation at baseline (HRSD item 3>2)
  • ECT treatment within 12 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01658150


Locations
Layout table for location information
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Brain & Behavior Research Foundation
Investigators
Layout table for investigator information
Principal Investigator: Katherine Burdick, PhD Icahn School of Medicine at Mount Sinai
  Study Documents (Full-Text)

Documents provided by Katherine Burdick, Icahn School of Medicine at Mount Sinai:

Layout table for additonal information
Responsible Party: Katherine Burdick, Principal Investigator, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT01658150    
Other Study ID Numbers: GCO 12-0679
HSM# 12-00311
First Posted: August 6, 2012    Key Record Dates
Results First Posted: December 5, 2018
Last Update Posted: December 5, 2018
Last Verified: November 2018
Keywords provided by Katherine Burdick, Icahn School of Medicine at Mount Sinai:
Cognition
Schizophrenia
Schizoaffective disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Isradipine
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents